Broncus Holding

Broncus Holding FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Broncus Holding (2216.HK) as of Nov 4, 2026 is 56.14 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 67.46 % — a change of -16.78% (lower).

FCF Conversion

56.14 %

YoY

-16.78%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Broncus Holding is 2025 56.14 % . FCF Conversion Rate (FCF/EBITDA) of Broncus Holding was 2024 67.46 % . It decreases by -16.78% lower compared to the previous year.

The Broncus Holding FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2019
49.73 USD
Jan 1, 2020
34.75 USD
Jan 1, 2021
14.13 USD
Jan 1, 2022
113.46 USD
Jan 1, 2023
95.53 USD
Jan 1, 2024
67.46 USD
Jan 1, 2025
56.14 USD
The Broncus Holding FCF Conversion history
YEARFCF ConversionYoY
56.14 %-16.78%
67.46 %-29.38%
95.53 %-15.80%
113.46 %+702.91%
14.13 %-59.33%
34.75 %-30.12%
49.73 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Broncus Holding Stock analysis

What does Broncus Holding do? Broncus Holding Corp generates revenue through the sale of medical device and consumable products across multiple therapeutic areas. The company's diagnostic solutions include FleXNeedle, ATV Sheath, and ATV Balloon, targeting healthcare providers for diagnostic procedures. Lung cancer treatment solutions feature InterVapor for lung cancer and H-Marker, sold to hospitals and oncology centers. Chronic obstructive pulmonary disease (COPD) solutions consist of InterVapor for COPD and TLD Ablation System, marketed to respiratory care facilities. Navigation platforms like Lungpoint, Lungpro, and New Generation Navigation Platform are supplied to medical institutions requiring advanced imaging guidance. The firm's product portfolio is structured around four key solution areas: diagnostics, lung cancer treatment, COPD management, and navigation systems. Diagnostic tools such as FleXNeedle and ATV products are used in minimally invasive procedures, while InterVapor serves dual purposes for both lung cancer and COPD applications. The TLD Ablation System is specifically designed for COPD treatment, and navigation platforms support precise procedural guidance in respiratory interventions. Broncus Holding Corp's primary customers are healthcare institutions including hospitals, specialized oncology centers, and respiratory care facilities. These entities purchase the company's medical devices and consumables for clinical use in treating respiratory conditions. The company's commercialization strategy focuses on direct sales to medical facilities rather than through third-party distributors, ensuring consistent product application and support. Broncus Holding is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Broncus Holding stock

FCF Conversion Rate (FCF/EBITDA) of Broncus Holding is 56.14 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Broncus Holding changed from 67.46 % to 56.14 %, representing a -16.78% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Broncus Holding since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Broncus Holding with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Broncus Holding

All Key Metrics — Broncus Holding